AbCellera Biologics Aktie [WKN DE: A2QKXS / ISIN: CA00288U1066]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu AbCellera Biologics Inc Registered Shs

21.11.24		AbCellera to Present at Upcoming Investor Conferences in December and January (Businesswire)
04.11.24		AbCellera Reports Q3 2024 Business Results (Businesswire)
22.10.24		AbCellera to Present at Upcoming Investor Conferences in November 2024 (Businesswire)
04.10.24		AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 (Businesswire)
26.09.24		AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 (Businesswire)
29.08.24		AbCellera to Present at Upcoming Investor Conferences in September (Businesswire)
06.08.24		AbCellera Reports Q2 2024 Business Results (Businesswire)
31.07.24		AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines (Businesswire)
25.06.24		AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 (Businesswire)
28.05.24		AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (Businesswire)
07.05.24		AbCellera Reports Q1 2024 Business Results (Businesswire)
01.05.24		AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies (Businesswire)
08.04.24		AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 (Businesswire)
03.04.24		AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 (Businesswire)
16.11.23		AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 (Businesswire)
03.11.23		AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 (Businesswire)
02.11.23		AbCellera Reports Q3 2023 Business Results (Businesswire)
01.11.23		Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology (Businesswire)
31.10.23		AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023 (Businesswire)
11.10.23		AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023 (Businesswire)
27.09.23		AbCellera Announces Two T-Cell Engager Presentations at SITC 2023 (Businesswire)
20.09.23		AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron (Businesswire)
13.09.23		AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology (Businesswire)
24.07.23		AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing (Businesswire)
06.07.23		AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023 (Businesswire)
29.05.23		AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 (Businesswire)
24.05.23		AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients (Businesswire)
04.05.23		AbCellera Reports Q1 2023 Business Results (Businesswire)
17.04.23		AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023 (Businesswire)
11.04.23		AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023 (Businesswire)
06.04.23		AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023 (Businesswire)
22.03.23		AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease (Businesswire)
14.03.23		AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023 (Businesswire)
23.02.23		AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023 (Businesswire)
21.02.23		AbCellera Reports Full Year 2022 Business Results (Businesswire)
01.02.23		AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 (Businesswire)
24.01.23		AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 (Businesswire)
20.01.23		AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent (Businesswire)
04.01.23		AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 (Businesswire)
15.12.22		AbCellera Up 5% Following Deal With AbbVie (RTTNews)
15.12.22		AbCellera and AbbVie Partner to Advance New Antibody Therapies (Businesswire)
01.12.22		AbCellera, Rallybio To Develop, And Commercialize Antibody-Based Therapeutics For Rare Diseases (RTTNews)
01.12.22		AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases (Businesswire)
01.12.22		FDA Pulls Emergency Use Authorization For Lilly's COVID-19 Antibody Drug (RTTNews)
10.11.22		AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 (Businesswire)
08.11.22		AbCellera Reports Q3 2022 Business Results (Businesswire)
04.11.22		AbCellera to Present at Upcoming Investor Conferences in November (Businesswire)
02.11.22		AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development (Businesswire)
11.10.22		AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022 (Businesswire)
05.10.22		AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022 (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 16:40
Kaufwert:	EUR
	Hinzufügen Speichern